ANPEP and acute lymphoblastic leukemia: In B-ALL, CD13 (29.8%) was the most common aberrant myeloid marker followed by CD15(20.3%) and CD 33 (17.2%), while CD15, CD 13 and CD 33 were expressed in 8.3%, 8.1% and 7.5% of T-ALL cases respectively.